The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures were adjudicated. RESULTS: Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001). The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 of 2047 patients [10.6%]; P=0.04), and the risk of hip fracture was lower by 38% (41 of 2046 patients [2.0%] vs. 66 of 2047 patients [3.2%]; P=0.02). Overall adverse events and serious adverse events were balanced between the two groups. During year 1, positively adjudicated serious cardiovascular adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. CONCLUSIONS: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, major cardiac events were observed in the ARCH study, while headaches, arthralgia, and injection site reactions were also observed [89,90].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As of 2021, it has reached Phase III trials, which have shown an increase in bone mineral density and a decrease in vertebral and hip fractures.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ARCH study showed a 48% lower risk of new vertebral fractures in the group that received romosozumab and alendronate than in the alendronate-only group [89].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,000
Mechanical Load, Sex Hormones, and Bone Modeling
Windahl, S. H., & Lerner, U. H. (2021) · Wiley eBooks · doi:10.1002/9781119608912.ch7 · Cited by 7
Gao, G., Cui, J., Xie, Y., & Dong, J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1440948 · Cited by 6
Cuadra-Llopart, L., Sierra, T. P., Sáez-López, P., Etxebarría-Foronda, Í., & Rey, J. R. C. (2024) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2024.101582 · Cited by 6
Assessing the Efficacy of Romosozumab in Postmenopausal Osteoporosis
Lladó, B., García, M. S. M., Herrera, S. R., Dubuc, C. A. E., Mariscal, G., & Mateu, J. B. (2025) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000002241 · Cited by 6
Li, D., Liu, F., Hou, Y., & Zeng, Y. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00921-6 · Cited by 6
Novel therapies in osteoporosis – Clinical update – 2025
Inderjeeth, C. A., & Inderjeeth, D. C. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102100 · Cited by 7
Considerations regarding the use of romosozumab in a patient at high risk for cardiovascular disease
McClung, M. R. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf164 · Cited by 6
Protásio, J., Pires, V. C., & Castro, M. G. M. (2025) · Diabetology · doi:10.3390/diabetology6110140 · Cited by 6
Lin, Y., Xu, Y., Zhou, S., Liu, J., Zhang, M., Zhang, B., & Chen, H. (2025) · Pharmaceuticals · doi:10.3390/ph18121809 · Cited by 6
Low Vitamin K Status, High Sclerostin and Mortality Risk of Stable Coronary Heart Disease Patients
Mayer, O., Bruthans, J., Seidlerová, J., Gelžinský, J., Kučera, R., Karnosová, P., Mateřánková, M., Rychecká, M., Wohlfahrt, P., Cífková, R., et al. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0168 · Cited by 6
Macías, J. G., & Olmos, J. M. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.04.015 · Cited by 6
Current Status of Mineral and Bone Disorders in Transplant Recipients
Elder, G. J. (2023) · Transplantation · doi:10.1097/tp.0000000000004538 · Cited by 6
Kwon, Y., Fang, Y., Lee, S., & Lee, C. (2023) · Applied Sciences · doi:10.3390/app13095426 · Cited by 6
Marino, S., Ozgurel, S. U., McAndrews, K., Cregor, M. D., Villaseñor, A., Mamani‐Huanca, M., Barbas, C., Gortázar, A. R., Sato, A. Y., & Bellido, T. (2024) · Bone · doi:10.1016/j.bone.2024.117042 · Cited by 6
Sahota, O., Narayanasamy, M. J., Bastounis, A., Paskins, Z., Bishop, S., Langley, T. E., Gittoes, N. J. L., Davis, S., Baily, A., Holmes, M., et al. (2024) · Health Technology Assessment · doi:10.3310/wypf0472 · Cited by 6
Larose, G., Al‐Azazi, S., Lix, L. M., Bohm, É., & Leslie, W. D. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07131-3 · Cited by 6
Anabolic treatment for osteoporosis and fragility fracture risk: one year in review 2024
Mattia, G. D., Maffi, M., & Mazzantini, M. (2024) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/7f52vl · Cited by 6
Signaling pathways associated with Lgr6 to regulate osteogenesis
King, J. S., Wan, M., Wagley, Y., Stestiv, M., Kalajzić, I., Hankenson, K. D., & Sanjay, A. (2024) · Bone · doi:10.1016/j.bone.2024.117207 · Cited by 6
Inokuchi, S., & Shimamoto, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1411285 · Cited by 6
Kawaguchi, H. (2024) · Calcified Tissue International · doi:10.1007/s00223-024-01267-4 · Cited by 6
Zhang, S., Liu, Y., Yu, W., & Gu, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1436486 · Cited by 6
The Challenge of Fractures in Patients With Chronic Kidney Disease
Kattah, A. G., Titan, S., & Wermers, R. A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.12.018 · Cited by 6
Lee, S., Hong, N., Cho, S., Shin, S., & Rhee, Y. (2025) · Osteoporosis International · doi:10.1007/s00198-024-07336-6 · Cited by 6
Mun, H. W., Lee, J. J., Shin, H., Kim, T.-H., Kim, S. W., & Oh, J. K. (2025) · Neurospine · doi:10.14245/ns.2449228.614 · Cited by 6
Nanomaterials‐Based Drug Delivery Systems for Therapeutic Applications in Osteoporosis
Shi, D., Li, Y., Tian, M., Xue, M., Wang, J., & An, H. (2025) · Advanced Biology · doi:10.1002/adbi.202400721 · Cited by 7
A History of Pivotal Advances in Clinical Research into Bone and Mineral Diseases
Cummings, S. R., & Eastell, R. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3353 · Cited by 6
Liu, J., Laster, A. J., Xu, X., Guo, H., Oates, M. K., & Gandra, S. R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4439 · Cited by 6
Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
Khanjee, N., & Maalouf, N. M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac159 · Cited by 6
Kim, K. J., Hong, N., Lee, S., Shin, S. H., & Rhee, Y. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06668-z · Cited by 6
Effect of different forms of selenium in osteoporosis rat model induced by retinoic acid
Li, H., Guo, Y. P., Chen, X., Man, Z., & Zhang, X. (2023) · Food Quality and Safety · doi:10.1093/fqsafe/fyad017 · Cited by 6
Dai, Z., Zhu, R., Sheng, Z., Qin, G., Luo, X., Qin, Q., Song, C., Li, L., Jin, P., Yang, G., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168757 · Cited by 6
Loss of Nmp4 enhances bone gain from sclerostin antibody administration
Korff, C., Adaway, M., Atkinson, E. G., Horan, D. J., Klunk, A. J., Silva, B. S., Bellido, T., Plotkin, L. I., Robling, A. G., & Bidwell, J. P. (2023) · Bone · doi:10.1016/j.bone.2023.116891 · Cited by 6
Sekundäre Frakturprävention/Update Leitlinie Osteoporose 2023 des Dachverbandes Osteologie
Stumpf, U. C., & Schmidmaier, R. (2024) · Die Unfallchirurgie · doi:10.1007/s00113-024-01415-3 · Cited by 6
Osteoporose – Implikation der neuen Leitlinie in die Praxis
Siggelkow, H., & Thomasius, F. E. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2127-2927 · Cited by 6
Wong, S. C., Straub, V. W., Ward, L. M., Quinlivan, R. C. M., Adachi, J., Ahmed, S. F., Anderton, M., Broggi, F., Crabtree, N. J., de Groot, I. J. M., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.01.002 · Cited by 6
Efficacy and safety of Zuogui Pill in treating osteoporosis
Chen, G., Zhang, Z., Liu, Y., Lu, J., Qi, X., Fang, C., & Zhou, C. (2019) · Medicine · doi:10.1097/md.0000000000013936 · Cited by 6
Sclerostin antibodies as novel anabolic therapy for osteoporosis
Mamedova, E., Grebennikova, T. A., Belaya, Z. E., & Rozhinskaya, L. Y. (2019) · Osteoporosis and Bone Diseases · doi:10.14341/osteo10127 · Cited by 6
Management of Osteoporosis in Women with Breast Cancer
Shapiro, C. L. (2020) · Breast Cancer Management · doi:10.2217/bmt-2020-0012 · Cited by 6
Glucocorticoids: A Review of its Adverse Effects Including Bone Loss
Dua, A., Das, P., & Ravindran, V. K. (2019) · Indian Journal of Rheumatology · doi:10.4103/0973-3698.272158 · Cited by 6
Watanabe, H., Ikoma, T., Sotome, S., & Okawa, A. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb02050h · Cited by 6
The Effects of Trends in Osteoporosis Treatment on the Incidence of Fractures
Horikawa, A., Miyakoshi, N., Hongo, M., Kasukawa, Y., Shimada, Y., Kodama, H., & Sano, A. (2021) · Journal of Osteoporosis · doi:10.1155/2021/5517247 · Cited by 6
Seeman, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00011-7 · Cited by 6
Orthogeriatrics and Hip Fractures
Sanford, A. M., Morley, J. E., & McKee, A. M. (2018) · The journal of nutrition health & aging · doi:10.1007/s12603-018-1007-7 · Cited by 6
Bones, heart and the new anabolic agent romosozumab
Pazianas, M. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136699 · Cited by 6
Damm, T., Libanati, C. R., Peña, J. A., Hanley, D. A., Bolognese, M. A., Recknor, C. P., & Glüer, C. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf119 · Cited by 5
Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma
Massat, B., Stiff, P. J., Esmail, F., Mariotti, E. G., & Hagen, P. A. (2025) · Cells · doi:10.3390/cells14161263 · Cited by 5
Savelli, G., Oliviero, S., Viceconti, M., & Mattina, A. A. L. (2025) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2025.107182 · Cited by 5
Yang, Y.-J., Wang, N., Wang, X., Guo, J., Yang, B., Jia, X., & Feng, L. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202504047 · Cited by 5
Jurnečka, D., Hrovatin, M., Bokalj, B., & Turk, B. (2026) · FEBS Journal · doi:10.1111/febs.70514 · Cited by 5
Patel, K., Salama, S., & Cottreau, J. M. (2022) · Orthopaedic Nursing · doi:10.1097/nor.0000000000000899 · Cited by 5
Kwon, Y., Fang, Y., Kim, H., Park, S., & Lee, C. (2024) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2024.05.009 · Cited by 5
Lewiecki, E. M., Bilezikian, J. P., Clark, A., Collins, M. T., Kado, D. M., Lane, J. M., Langdahl, B. L., McClung, M. R., Snyder, P. J., & Stein, E. M. (2024) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2024.101559 · Cited by 5
Tominaga, R., Ikenoue, T., Ishii, R., Niihata, K., Aita, T., Okuda, T., Shimizu, S., Taguri, M., & Kurita, N. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf010 · Cited by 5
RetractedPark, J. Y., Park, H. M., Song, J., Hwang, K. J., Kim, M.-R., & Chung, Y. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14092958 · Cited by 5
Haroon, S., Cobb, C., Sufian, S., Jain, R., Maalouf, N. M., & Putman, M. S. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.011 · Cited by 5
National guidelines for diagnosis and treatment of osteoporosis in Slovakia
Payer, J., Jackuliak, P., Vaňuga, P., Killinger, Z., Dubecká, S., & Kužma, M. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01538-z · Cited by 5
Legault, M., Hartford, J., Arsenault, B. J., Yang, A. Y., & Pineau, J. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.04.010 · Cited by 7
Rippl, M., Grupp, P., Martini, S., Müller, K. J., Schluessel, S., Schmidmaier, R., Tausendfreund, O., Tümena, T., & Drey, M. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07540-y · Cited by 5
Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?
Gavrilov, Z., & Lojk, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146924 · Cited by 7
A pharmacist-run anabolic osteoporosis clinic: An abaloparatide descriptive report
McGreevy, J. L., Kane, M. P., Busch, R. S., Bakst, G., & ElDeiry, S. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.03.017 · Cited by 5
Medication-Related Osteonecrosis of the Jaws: A Literature Review
Kim, G.-M., Moon, S., You, J., Kim, G.-Y., & Oh, J. (2022) · Journal of Oral Medicine and Pain · doi:10.14476/jomp.2022.47.1.1 · Cited by 5
Update der S3-Leitlinie Diagnostik, Prophylaxe und Therapie der Osteoporose
Drey, M., Otto, S., Thomasius, F. E., & Schmidmaier, R. (2024) · Die Orthopädie · doi:10.1007/s00132-024-04522-6 · Cited by 5
Atypical femur fracture following romosozumab and bisphosphonate treatment
Jacunski, M., Johnsson, H. J., Ralston, S. H., & Hauser, B. (2024) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715241301487 · Cited by 5
Lanzolla, G., Sabini, E., Beigel, K., Khan, M. P., Liu, X. S., Wang, D., Laslow, B., Taylor, D. M., Bellido, T., Giaccia, A. J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416004121 · Cited by 5
Rheuma und Knochenstoffwechsel
Dischereit, G., & Lange, U. (2019) · Der Orthopäde · doi:10.1007/s00132-019-03809-3 · Cited by 5
Sclerostin Inhibition in the Treatment of Osteoporosis
Baron, R., Gori, F., & Leder, B. Z. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_19 · Cited by 5
Jakob, F. J. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1213-2245 · Cited by 5
Risks vs. benefits of switching therapy in patients with postmenopausal osteoporosis
Ishizu, H., Arita, K., Terkawi, M. A., Shimizu, T., & Iwasaki, N. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1956902 · Cited by 5
Drug Treatment of Low Bone Mass and Other Bone Conditions in Pediatric Patients
Costi, S., Giani, T., Orsini, F., & Cimaz, R. (2022) · Pediatric Drugs · doi:10.1007/s40272-021-00487-7 · Cited by 5
Pharmacological treatment of osteoporosis: 2022 update
Jeon, Y. K., & Kim, I. J. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.4.241 · Cited by 5
Where is bone science taking us?
Langdahl, B. L., Uitterlinden, A. G., & Ralston, S. H. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101791 · Cited by 5
Diagnose und Management der Osteoporose bei Diabetes mellitus (Update 2019)
Muschitz, C., Kautzky‐Willer, A., Rauner, M., Winhofer-Stöckl, Y., & Haschka, J. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1462-0 · Cited by 5
Metal ion toxicity in the skeleton: lead and aluminum
Puzas, J. E., & Boyce, B. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00022-1 · Cited by 5
Deal, C. L., Mitlak, B., Wang, Y., Fitzpatrick, L. A., & Miller, P. D. (2019) · Bone Reports · doi:10.1016/j.bonr.2019.100230 · Cited by 5
Recent developments towards closing the gap in osteoporosis management
Miedany, Y. M. E. (2021) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-020-00048-9 · Cited by 5
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_27 · Cited by 5
Biver, E., & Ferrari, S. (2020) · JMIG · doi:10.53738/revmed.2020.16.676-77.0078 · Cited by 5
Mesquita, P. N., Maia, J. M. C., Andrade, S. R. D. L., & Bandeira, F. A. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_24 · Cited by 5
Arboleya, L. R., Trujillo, J. M. C., Chaves, C., Duaso, E., Mesa-Ramos, M., & Olmos, J. M. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01318-7 · Cited by 5
Saag, K. G., Curtis, J. R., & Reid, I. R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4000 · Cited by 5
Self-citationGittoes, N. J. L., & Eastell, R. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198851899.003.0006 · Cited by 5
Riancho, J., Peris, P., González-Macı́as, J., & Pérez-Castrillón, J.-L. (2022) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2022000100002 · Cited by 4
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause
Palacios, S., Rodríguez, S. P. G., Prieto, M. S., & Fasero, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2383639 · Cited by 4
Actividades preventivas en la mujer. Actualización PAPPS 2024
García‐Franco, A. L., Alonso‐Coello, P., Iglesias, A. P., Fernádez, C. G., Pineda, E. R., & Goñi, J. L. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103131 · Cited by 4
Research Progress on the Influence of Novel Targeted Drugs for Osteoporosis on Glucose Metabolism
Meng, L., Sun, L., & Li, M. (2025) · Biomolecules · doi:10.3390/biom15030331 · Cited by 4
Yang, X., Li, Y., Guo, J., Wang, J., Li, S., Yang, Z., Niu, P. C., Jiang, Y., Song, M., & Hai, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1530194 · Cited by 4
Epidemiology, Pathophysiology and Management of Atypical Femur Fractures: an Update
Collins, L., Nguyen, H. H., Milat, F., & Ebeling, P. R. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00932-3 · Cited by 4
Hasebe, M., Su, C., Kiel, D. P., & Yoshiji, S. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00941-2 · Cited by 5
Yang, Y., Zheng, J., Lu, Q., Kuang, Y., Diao, J., & Zhao, N. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102401 · Cited by 4
Liu, E., & Liu, R. Y. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2596764 · Cited by 4
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Adami, G., Pollastri, F., Fassio, A., Montanari, F., Piccinelli, A., Benini, C., Pasetto, E., Dartizio, C., Gatti, D., Rossini, M., et al. (2025) · Arthritis & Rheumatology · doi:10.1002/art.70002 · Cited by 4
Castagna, A., Pujia, C., Mazza, E., Maurotti, S., Ferro, Y., Rizzo, V., Formica, M., Conforto, R., Mercuri, C., Sciacqua, A., et al. (2026) · Nutrients · doi:10.3390/nu18020262 · Cited by 4
Yeon, S., Seto, S. W., Bhuyan, D. J., Chang, D., Li, C. G., & Low¹, M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01377-w · Cited by 4
Mechanisms underlying the waning of osteoanabolic therapy effects in osteoporosis
Ferrari, S., Thouverey, C., & Gerbaix, M. (2026) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjag053 · Cited by 4
Cipolloni, V., Bonifacio, M., Hassny, S. M., Melara, G., Lucchetti, L., Gentile, M., & Conforti, A. (2026) · Medicina · doi:10.3390/medicina62040687 · Cited by 4
Protein- and Cell-Based Therapies for Periodontal Regeneration
Zhao, L., Cho, Y., Kauffmann, F., Sarment, L., Beitz, J., Kaigler, D., & Giannobile, W. V. (2020) · Springer eBooks · doi:10.1007/978-3-030-42990-4_14 · Cited by 4
Bonewald, L. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00007-1 · Cited by 8
Diagnose und Management der Osteoporose bei Diabetes mellitus (Update 2023)
Muschitz, C., Kautzky‐Willer, A., Winhofer, Y., Rauner, M., Haschka, J., Cejka, D., Wakolbinger, R., & Pietschmann, P. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02118-8 · Cited by 4
P7C3 Ameliorates Bone Loss by Inhibiting Osteoclast Differentiation and Promoting Osteogenesis
Tian, B., Bai, J., Sheng, L., Chen, H. H., Chang, W., Zhang, Y., Yao, C., Zhou, C., Wang, X., Shan, H., et al. (2023) · JBMR Plus · doi:10.1002/jbm4.10811 · Cited by 4
Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta
Wang, Y., Hu, J. R., Sun, L., Zhou, B., Lin, X., Zhang, Q., Wang, O., Jiang, Y., Xia, W., Xing, X., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02380-9 · Cited by 4
Metadata
- Authors
- Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A.
- Affiliations
- Inserm (FR)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-12
- Volume
- 377
- Issue
- 15
- Pages
- 1417-1427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2754720807
- Cited by
- 1,544
- References
- 31
- Citations by year
- 2026: 204 · 2025: 216 · 2024: 210 · 2023: 148 · 2022: 179 · 2021: 172 · 2020: 185 · 2019: 114 · 2018: 94 · 2017: 19
- FWCI
- 123.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Teva Pharmaceutical Industries
- Radius Health
- Medac
- Chugai Pharmaceutical
- Amgen Canada
- UCB Pharma
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- romosozumab, alendronate, osteoporosis, fracture prevention, sclerostin inhibition, postmenopausal women, vertebral fractures, hip fracture, non-vertebral fractures, bisphosphonates, cardiovascular adverse events, osteonecrosis of the jaw, atypical femoral fractures, bone formation, bone resorption, fragility fractures, open-label extension
- MeSH terms
- Aged, Antibodies, Monoclonal, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Least-Squares Analysis, Spinal Fractures, Bone Remodeling, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
